A New Approach to Hair Loss Grounded in Stem Cell Biology
We target the hair follicle directly to stimulate growth
Innovative Science
Based on UCLA scientists' groundbreaking discovery that hair follicle stem cells have a unique metabolic switch, Pelage's platform is the first to target this novel mechanism to activate stem cells and regrow hair.
For Everyone
By targeting the intrinsic metabolic properties of hair follicle stem cells, Pelage's treatment has potential to induce robust hair growth for all genders, skin types, and hair types.
Non-Invasive
The small molecule drug platform stimulates hair growth without the need for invasive procedures or oral systemic exposure.
Our Mission
At Pelage, our goal is to deliver a clinically-tested treatment grounded in innovative science for all genders, skin types, and hair types. Based on breakthrough discoveries by Pelage co-founders, we activate hair growth through a first-in-class mechanism that targets the metabolism of hair follicle stem cells.
Types of Hair Loss
Androgenetic Alopecia
Female and Male pattern baldness
More than 90% of all hair loss cases
*Target Therapy
Chemotherapy
Drug-induced
hair loss
*Target Therapy
Telogen Effluvium
Stress-induced hair loss
*Target Therapy
Alopecia Areata
Autoimmune-induced
hair loss
Scarring Alopecia
Includes autoimmune
conditions and scalp injury
Current Hair Loss
Treatments Are Inadequate
Existing therapies target external factors affecting hair growth (e.g. anti-androgen drugs like finasteride Propecia)
Current treatments have limited efficacy and unclear mechanism of action (e.g. minoxidil Rogaine and platelet-rich plasma PRP). Most are not FDA-approved.
Treatment options are not suitable for all patients and can be invasive or require oral dosing (e.g. spironolactone, hair transplantation)
The Pelage Solution
A novel, non-invasive, topical small molecule drug platform that activates stem cells in the hair follicles directly to stimulate robust hair growth. By targeting an intrinsic metabolic switch in hair follicles, Pelage’s platform is suitable for all genders, skin types, and hair types.
How Our Drug Works
Hair follicle stem cells (HFSCs) undergo cycles of dormancy and activation to power hair growth.
In alopecia related to age, stress, hormones, and chemotherapy, hair follicle stem cells can become "stuck" in the dormant phase and unable to trigger hair growth. However, these stem cells are still present and viable in the follicles.
Our drug activates dormant hair follicle stem cells, restoring the regenerative capacity of the follicle and triggering new hair growth.
Press
- Pioneers novel approach to restore the body’s natural ability to grow hair by reactivating dormant hair follicle stem cells
- Phase I clinical data meets primary safety endpoints and shows statistically significant stem cell activation in hair follicles after one week of treatment with PP405; Phase 2 clinical trial to begin in mid-2024
- Announces the appointment of Qing Yu Christina Weng, M.D., as Chief Medical Officer
- Potent topical MPC inhibitor, based on discovery of a metabolic switch, reawakens dormant hair follicle stem cells to stimulate hair growth
- PP405 demonstrates statistically significant activation of Ki67 in the hair follicle, a well-established marker of stem cell proliferation